Please assess the completion status of the following clinical trial:

Trial Title: ErbB2 Over-expressing Metastatic Breast Cancer Study Using Paclitaxel, Trastuzumab, and Lapatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Histologically confirmed invasive breast cancer with stage IV disease~* If trastuzumab was administered in the adjuvant setting, \>12 months must have elapsed since discontinuation of trastuzumab therapy~* If a taxane was administered in the neoadjuvant or adjuvant setting, progression must have occurred ≥12 months after completion of this treatment~* Had tumors that overexpress ErbB2 defined as either: 3+ by IHC OR c-erbB2 gene amplification by FISH OR 0, 1+, 2+ by IHC and c-erbB2 gene amplification by FISH.~* Patients must have tumor tissue available for central testing, and must have Measurable lesion(s) according to RECIST~* Subjects must be females of at least 18 years Non-childbearing potential or Childbearing potential but using adequate contraception~* Radiotherapy to a limited area other than the sole site of measurable and assessable disease is allowed; however, patients must have completed treatment and recovered from all acute treatment-related toxicities prior to administration of the first dose of study medication~* Bisphosphonate therapy for bone metastases is allowed; however, treatment must be initiated prior to the first dose of randomized therapy. Prophylactic use of bisphosphonates in patients without bone disease is not permitted, except for the treatment of osteoporosis~* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1~* For those patients whose disease is estrogen receptor positive+ and/or progesterone receptor + one the following criteria should be met: Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases) or Rapidly progressing/life threatening disease, as determined by the investigator or Patients who received hormonal therapy and are no longer benefiting from this therapy;~* Able to swallow and retain oral medication~* Cardiac ejection fraction within institutional range of normal~* Patient must have adequate organ function~Exclusion criteria:~* Pregnant or lactating females;~* Received prior chemotherapy, immunotherapy, biologic therapy, or anti-ErbB1/ErbB2 therapy for metastatic disease, prior hormonal therapy is permitted but must be discontinued a minimum of 7 days prior to randomization;~* Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Patients with ulcerative colitis are also excluded;~* History of other malignancy; however, patients who have been disease-free for five years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;~* Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical disorder that would interfere with the patient's safety;~* Unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or of prior cancer treatment;~* Peripheral neuropathy of Grade 2 or greater;~* Active or uncontrolled infection;~* Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent;~* Known history of uncontrolled or symptomatic angina, arrhythmias, conduction abnormalities or congestive heart failure;~* Known history or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis;~* Concurrent cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy);~* Concurrent treatment with an investigational agent or participation in another clinical trial;~* Concurrent treatment with any medication on the prohibited medications list.~* Used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of treatment. Hormonal therapy needs to be discontinued at least 7 days before the first dose of treatment.~* Prior therapy with an ErbB2 inhibitor, other than trastuzumab in the adjuvant setting;~* A known immediate or delayed hypersensitivity reaction to drugs chemically related to lapatinib or excipients;~* A known immediate or delayed hypersensitivity reaction to drugs chemically related to paclitaxel or excipients;~* A known immediate or delayed hypersensitivity reaction to drugs chemically related to trastuzumab or excipients;~* Non compliance with any of the screening procedures

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants received: paclitaxel 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily
- Cohort 2 (Type: EXPERIMENTAL): Participants received paclitaxel 70mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 1000 mg PO daily.
- Cohort 3 (Type: EXPERIMENTAL): Participants in this arm received 80mg/m2 IV weekly for 3 weeks of a 4 week cycle plus trastuzumab 4 mg/kg IV loading dose and 2 mg/kg IV weekly plus lapatinib 750 mg PO

Based on this trial design, predict the completion outcome and termination type (if applicable).